Core Viewpoint - Curis, Inc. is making significant progress in its clinical programs, particularly with emavusertib, an IRAK4 inhibitor, showing promising results in combination therapies for various cancers, setting a positive outlook for 2025 [2][3]. Clinical Developments - Emavusertib demonstrated efficacy in a study involving patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), with 3 complete responses and 1 unconfirmed complete response among 10 evaluable patients [3]. - The company plans to present additional clinical data from the TakeAim Leukemia study at the upcoming ASH annual meeting [4][5]. Financial Performance - For Q3 2024, Curis reported a net loss of $10.1 million, or $1.70 per share, an improvement from a net loss of $12.2 million, or $2.13 per share, in Q3 2023 [6]. - Revenues for Q3 2024 were $2.9 million, slightly up from $2.8 million in the same period last year, primarily from royalty revenues [7]. - Research and development expenses decreased to $9.7 million in Q3 2024 from $10.4 million in Q3 2023, attributed to lower consulting and employee-related costs [8]. Cash Position - Following a recent offering, Curis's cash and cash equivalents totaled $31.6 million, which is expected to support operations into mid-2025 [11].

Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3] - Emavusertib is currently in clinical trials, including the Phase 1/2 TakeAim Lymphoma study for relapsed/refractory primary central nervous system lymphoma (PCNSL) and the Phase 1/2 TakeAim Leukemia study for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (hrMDS) [3] - The drug has received Orphan Drug Designation from the U.S. FDA for treating AML and MDS [3] Upcoming Financial Results - Curis will report its third quarter 2024 financial and operating results on November 14, 2024, at 8:00 a.m. ET [1] - A conference call and webcast will follow at 8:30 a.m. ET on the same day [1][2] Collaboration and Licensing - Curis has an exclusive license to emavusertib through a collaboration with Aurigene established in 2015 [3] - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3]

Core Viewpoint - Curis, Inc. has announced a definitive agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $12.1 million to support its research and development efforts [1][2]. Group 1: Offering Details - Curis will sell 2,398,414 shares of common stock at a combined purchase price of $5.045 per share, which includes unregistered warrants for the same number of shares with an exercise price of $4.92 [1][2]. - The offering is expected to close on or about October 30, 2024, pending customary closing conditions [2]. - Truist Securities and Laidlaw & Company (U.K.) Ltd. are acting as placement agents for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research, development, working capital, and other general corporate purposes [2]. Group 3: Company Background - Curis is focused on developing emavusertib, an orally available IRAK4 inhibitor, currently in clinical trials for various hematological malignancies [7]. - Emavusertib has received Orphan Drug Designation from the FDA for treating acute myeloid leukemia and myelodysplastic syndromes, as well as from the European Commission for primary central nervous system lymphoma [7].

Core Insights - Curis, Inc. is hosting the 3rd Annual Symposium on IRAK4 in Cancer on September 26, 2024, focusing on the potential of IRAK4 inhibition in cancer treatment [1][2] - The symposium will present updated data for 10 evaluable patients in the PCNSL study, with ongoing patient enrollment expected to reach 15-20 by year-end [3][4] - Emavusertib, an orally available IRAK4 inhibitor, is currently in clinical trials for various hematologic malignancies and has received Orphan Drug Designation from the FDA and European Commission [6] Company Overview - Curis, Inc. specializes in the development of emavusertib, which is being tested in multiple Phase 1/2 studies for conditions such as relapsed/refractory primary central nervous system lymphoma (PCNSL) and acute myeloid leukemia (AML) [6] - The company has an exclusive license for emavusertib through a collaboration with Aurigene and has previously licensed rights to Erivedge® to Genentech for advanced basal cell carcinoma treatment [6] Symposium Details - The symposium will feature prominent experts in oncology, including Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, discussing the biology of the IRAK4 pathway and its implications for cancer therapies [2][5] - The event is free and open to the public, aiming to foster discussion on the advancements in IRAK4 inhibition and its future development opportunities [1][2]

LEXINGTON, Mass., Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET. Details for the webcast can be found using the Cantor webcast link. The webcast will be also availa ...

LEXINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C. Wainwright 26th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows: Format: Company Presentation Date: Wednesd ...

Curis, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Yale Jen - Laidlaw Ed White - H.C. Wainwright Soumit Roy - JonesTrading Li Watsek - Cantor Operator Good morning, ladies and gentlemen. And welcome to the Curis Provides Second Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-o ...

Curis (CRIS) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -19.41%. A quarter ago, it was expected that this drug developer would post a loss of $1.94 per share when it actually produced a loss of $2.05, delivering a surprise of -5.67%. Over the last four quarters, the company has surpasse ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name o ...

Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2024 Financial and Operating Update EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., August 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024. Operationa ...